Clinical trialsCompany release

Jasper Therapeutics completes IgAN cohort enrolment as Kira deal closes and cash reaches $135.3M

🇺🇸 Jasper Therapeutics, Inc. (JSPR) · Mon 16 Nov 2026

The company reported Q3 2026 progress in its Phase 2 renal basket study of vensobafusp alfa, with interim IgA nephropathy data expected in the fourth quarter.

Jasper Therapeutics reported third-quarter 2026 results and a corporate update on 16 November, saying it has completed enrolment in the first IgA nephropathy (IgAN) cohort of its Phase 2 renal basket study of vensobafusp alfa.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Jasper Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Jasper Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →